253 related articles for article (PubMed ID: 28497319)
1. Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004-2015.
Laius O; Pisarev H; Maasalu K; Kõks S; Märtson A
Arch Osteoporos; 2017 Dec; 12(1):48. PubMed ID: 28497319
[TBL] [Abstract][Full Text] [Related]
2. Adherence to osteoporosis medicines in Estonia-a comprehensive 15-year retrospective prescriptions database study.
Laius O; Pisarev H; Maasalu K; Kõks S; Märtson A
Arch Osteoporos; 2017 Dec; 12(1):59. PubMed ID: 28643266
[TBL] [Abstract][Full Text] [Related]
3. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
Kristensen PK; Ehrenstein V; Shetty N; Pedersen AB
Osteoporos Int; 2019 Sep; 30(9):1817-1825. PubMed ID: 31263921
[TBL] [Abstract][Full Text] [Related]
4. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
5. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
[TBL] [Abstract][Full Text] [Related]
6. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012-2015.
Tamaki J; Fujimori K; Ikehara S; Kamiya K; Nakatoh S; Okimoto N; Ogawa S; Ishii S; Iki M;
Osteoporos Int; 2019 May; 30(5):975-983. PubMed ID: 30648192
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces.
Crilly RG; Kloseck M; Chesworth B; Mequanint S; Sadowski E; Gilliland J
Osteoporos Int; 2014 Jan; 25(1):205-10. PubMed ID: 23907572
[TBL] [Abstract][Full Text] [Related]
8. Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Laius O; Maasalu K; Kõks S; Märtson A
Medicina (Kaunas); 2016; 52(5):315-320. PubMed ID: 27789081
[TBL] [Abstract][Full Text] [Related]
9. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
[TBL] [Abstract][Full Text] [Related]
10. Cost-effective osteoporosis treatment thresholds in Greece.
Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
[TBL] [Abstract][Full Text] [Related]
11. Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010.
Klop C; Gibson-Smith D; Elders PJ; Welsing PM; Leufkens HG; Harvey NC; Bijlsma JW; van Staa TP; de Vries F
Osteoporos Int; 2015 Jul; 26(7):1919-28. PubMed ID: 25963232
[TBL] [Abstract][Full Text] [Related]
12. Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture.
Iba K; Takada J; Hatakeyama N; Kaya M; Isogai S; Tsuda H; Obata H; Miyano S; Yamashita T
J Orthop Sci; 2006 Oct; 11(5):446-9. PubMed ID: 17013730
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate use after clinical fracture and risk of new fracture.
Bergman J; Nordström A; Nordström P
Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
[TBL] [Abstract][Full Text] [Related]
14. The health and economic burden of osteoporotic fractures in Singapore and the potential impact of increasing treatment rates through more pharmacological options.
Chandran M; Lau TC; Gagnon-Arpin I; Dobrescu A; Li W; Leung MYM; Patil N; Zhao Z
Arch Osteoporos; 2019 Nov; 14(1):114. PubMed ID: 31773442
[TBL] [Abstract][Full Text] [Related]
15. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
[TBL] [Abstract][Full Text] [Related]
16. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
17. Establishing and evaluating FRAX
Chan DC; McCloskey EV; Chang CB; Lin KP; Lim LC; Tsai KS; Yang RS
J Formos Med Assoc; 2017 Mar; 116(3):161-168. PubMed ID: 27117886
[TBL] [Abstract][Full Text] [Related]
18. Fracture prevention in Kaiser Permanente Southern California.
Dell R
Osteoporos Int; 2011 Aug; 22 Suppl 3():457-60. PubMed ID: 21847765
[TBL] [Abstract][Full Text] [Related]
19. Low rates of osteoporosis treatment after hospitalization for hip fracture in Hawaii.
Nguyen ET; Posas-Mendoza T; Siu AM; Ahn HJ; Choi SY; Lim SY
Osteoporos Int; 2018 Aug; 29(8):1827-1832. PubMed ID: 29744567
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of fragility fractures in Sakaiminato, Japan: incidence, secular trends, and prognosis.
Tsukutani Y; Hagino H; Ito Y; Nagashima H
Osteoporos Int; 2015 Sep; 26(9):2249-55. PubMed ID: 25986382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
